Proinflammatory enzyme soluble epoxide hydrolase bridges obesity to colonic inflammation and potential carcinogenesis

Affiliations

Comment

Guang-Yu Yang. Proc Natl Acad Sci U S A. 2018.

. 2018 Jun 5;115(23):5827-5828.

doi: 10.1073/pnas.1807520115. Epub 2018 May 16.

¹ Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611 g-yang@northwestern.edu.

No abstract available

Conflict of interest statement

The author declares no conflict of interest.

Lipidomic profiling reveals soluble epoxide hydrolase as a therapeutic target of obesity-induced colonic inflammation.
Wang W, Yang J, Zhang J, Wang Y, Hwang SH, Qi W, Wan D, Kim D, Sun J, Sanidad KZ, Yang H, Park Y, Liu JY, Zhao X, Zheng X, Liu Z, Hammock BD, Zhang G. Wang W, et al. Proc Natl Acad Sci U S A. 2018 May 15;115(20):5283-5288. doi: 10.1073/pnas.1721711115. Epub 2018 May 1. Proc Natl Acad Sci U S A. 2018. PMID: 29717038 Free PMC article.

1. Wang W, et al. Lipidomic profiling reveals soluble epoxide hydrolase as a therapeutic target of obesity-induced colonic inflammation. Proc Natl Acad Sci USA. 2018;115:5283–5288. - PMC - PubMed
1. Zhang W, et al. Soluble epoxide hydrolase gene deficiency or inhibition attenuates chronic active inflammatory bowel disease in IL-10(-/-) mice. Dig Dis Sci. 2012;57:2580–2591. - PMC - PubMed
1. Zhang W, et al. Reduction of inflammatory bowel disease-induced tumor development in IL-10 knockout mice with soluble epoxide hydrolase gene deficiency. Mol Carcinog. 2013;52:726–738. - PMC - PubMed
1. Fischer SM, Hawk ET, Lubet RA. Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res (Phila) 2011;4:1728–1735. - PMC - PubMed
1. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340:1888–1899. - PubMed